[Molecular-biological properties of blood lymphocytes of Hodgkin's lymphoma patients. Plausible possibility of treatment effect prognosis].
Hodgkin's lymphoma (HL) patients were investigated before and during chemical and radiation therapy. The properties of peripheral blood lymphocytes of the HL patients before treatment have been compared with healthy donors and the patients during the treatment. The genetic damage--frequency of cells with micronuclei (MN), the level of DNA single- and double-strand breaks (SSB and DSB), DNA-protein cross-links (DPC) have been studied. Biochemical and physiological parameters have been compared as well: the concentration of reactive oxygen species (ROS), the ability to the adaptive response induction. The radiosensitivity of lymphocytes in vitro exposed to the 1 Gy irradiation has also been determined (by MN test). It was shown that in Hodgkin's lymphoma patients' lymphocytes (in comparison with healthy donors) the frequency of cells with MN does not change, the level of SSBs and DSBs increases, the amount of DPC does not change, and ROS concentration (on average) significantly increases because of the part of the population that have high ROS content. The ROS concentration decreases to control level, the frequency of cells with MN increases, the level of DSBs does not change but the level of DPCs (which prevents the determination of DSB) increases in the patients during treatment. It was also discovered that lymphocyte radiosensitivity correlates with the MN cells frequency before treatment and the ROS concentration. These results make it possible to suppose that the high MN frequency and high ROS concentration in Hodgkin's lymphoma patient lymphocytes (before treatment) can serve as prognostic factors for the effectiveness of radio and chemical therapy.
I I
II
Pelevina
A V
AV
Aleshchenko
M M
MM
Antoshchina
N Iu
NIu
Vorob'eva
O V
OV
Kudriashova
O E
OE
Lashkova
E Iu
EIu
Lizunova
A N
AN
Osipov
N I
NI
Riabchenko
A M
AM
Serebrianyĭ
V V
VV
Pavlov
D053903:DNA Breaks, Double-Stranded / Q000528:radiation effects; D053904:DNA Breaks, Single-Stranded / Q000528:radiation effects; D064420:Drug-Related Side Effects and Adverse Reactions; D006689:Hodgkin Disease / Q000097:blood* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism / Q000528:radiation effects*; D048629:Micronuclei, Chromosome-Defective / Q000528:radiation effects; D015162:Micronucleus Tests / Q000379:methods; D011379:Prognosis; D011836:Radiation Tolerance; D011878:Radiotherapy / Q000009:adverse effects*; D017382:Reactive Oxygen Species / Q000378:metabolism* / Q000528:radiation effects*
D017382:Reactive Oxygen Species